Lyell Net Tangible Assets from 2010 to 2025

LYEL Stock  USD 0.56  0.03  5.66%   
Lyell Immunopharma Net Tangible Assets yearly trend continues to be quite stable with very little volatility. Net Tangible Assets may rise above about 1 B this year. Net Tangible Assets is the total assets of Lyell Immunopharma minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. View All Fundamentals
 
Net Tangible Assets  
First Reported
2010-12-31
Previous Quarter
958.2 M
Current Value
B
Quarterly Volatility
501.3 M
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Lyell Immunopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Lyell Immunopharma's main balance sheet or income statement drivers, such as Net Interest Income of 12.8 M, Interest Income of 12.8 M or Depreciation And Amortization of 13.9 M, as well as many indicators such as Price To Sales Ratio of 2.5 K, Dividend Yield of 0.0 or PTB Ratio of 0.42. Lyell financial statements analysis is a perfect complement when working with Lyell Immunopharma Valuation or Volatility modules.
  
Check out the analysis of Lyell Immunopharma Correlation against competitors.
For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.

Latest Lyell Immunopharma's Net Tangible Assets Growth Pattern

Below is the plot of the Net Tangible Assets of Lyell Immunopharma over the last few years. It is the total assets of a company minus any intangible assets such as patents, copyrights, and goodwill; it represents the physical assets of a company. Lyell Immunopharma's Net Tangible Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Lyell Immunopharma's overall financial position and show how it may be relating to other accounts over time.
Net Tangible Assets10 Years Trend
Slightly volatile
   Net Tangible Assets   
       Timeline  

Lyell Net Tangible Assets Regression Statistics

Arithmetic Mean197,317,162
Coefficient Of Variation254.07
Mean Deviation446,762,098
Median(111,108,000)
Standard Deviation501,315,875
Sample Variance251317.6T
Range1.3B
R-Value0.78
Mean Square Error104993.4T
R-Squared0.61
Significance0.0004
Slope82,245,269
Total Sum of Squares3769764.1T

Lyell Net Tangible Assets History

2025B
2024958.2 M
2022833.3 M
2021929.8 M
2020-292.5 M

About Lyell Immunopharma Financial Statements

Lyell Immunopharma investors utilize fundamental indicators, such as Net Tangible Assets, to predict how Lyell Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
Last ReportedProjected for Next Year
Net Tangible Assets958.2 MB

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Lyell Immunopharma is a strong investment it is important to analyze Lyell Immunopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Lyell Immunopharma's future performance. For an informed investment choice regarding Lyell Stock, refer to the following important reports:
Check out the analysis of Lyell Immunopharma Correlation against competitors.
For more information on how to buy Lyell Stock please use our How to buy in Lyell Stock guide.
You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Lyell Immunopharma. If investors know Lyell will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Lyell Immunopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.31)
Quarterly Revenue Growth
(0.15)
Return On Assets
(0.22)
Return On Equity
(0.66)
The market value of Lyell Immunopharma is measured differently than its book value, which is the value of Lyell that is recorded on the company's balance sheet. Investors also form their own opinion of Lyell Immunopharma's value that differs from its market value or its book value, called intrinsic value, which is Lyell Immunopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Lyell Immunopharma's market value can be influenced by many factors that don't directly affect Lyell Immunopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Lyell Immunopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Lyell Immunopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Lyell Immunopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.